The United States seeks to obtain “adapted” vaccines

Pending approval from regulators, the US government will purchase jabs specifically “tailored” to the Covid-19 Omicron strain, Pfizer says

US health officials are expected to purchase more than $3 billion in additional coronavirus vaccines from pharmaceutical giant Pfizer, which noted the sale could include a new immunization designed to protect against the Omicron variant currently being reviewed by federal regulators.

Pfizer and its German partner BioNTech announced the latest vaccine deal on Wednesday afternoon, saying they would ship 105 million doses in exchange for $3.2 billion, with contract options for an additional 195 million vaccines if the government agreed to exercise them.

“This agreement will provide additional doses to US residents and help address the next wave of Covid-19,” said Sean Marett, director of BioNTech, adding that “Pending regulatory clearance, it will also include an Omicron-tailored vaccine, which we believe is important for combating the rapidly spreading Omicron variant.”

READ MORE: Reminders of Pfizer vaccines approved for the youngest

The companies said they provided the Food and Drug Administration (FDA) “Pivot data” on the “security” and “tolerance” of two candidate vaccines suitable for Omicron last weekend, indicating “positive” results of laboratory studies. Even before receiving approval, they have already started manufacturing doses of the two candidates “at risk” for “Start deliveries quickly after authorization.”

According to data collected by UNICEF, the vaccine developed by Pfizer and BioNTech is among the most widely used vaccines against the coronavirus and has been approved by some 111 countries. The vaccine has been a boon for pharmaceutical companies, becoming one of the most lucrative products in modern history and helping to double Pfizer’s annual revenue between 2020 and 2021.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button